Fabodrox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fabodrox

What is Fabodrox and What Type of Antibiotic is Azithromycin?

Fabodrox is a prescription-only medication (Rx) containing the single active ingredient Azithromycin, which functions as a systemic anti-infective agent. Azithromycin is classified as an azalide, a specialized synthetic compound derived from the broader macrolide antibiotic class. This classification is significant because the drug's structure, which features an inserted nitrogen atom, is designed to provide high tissue penetration and a prolonged presence in the body. The general purpose of Fabodrox is to control the spread and progression of susceptible bacterial infections.

Composition, Forms, and General Function

The composition of Fabodrox is a single-ingredient product, available in multiple dosage forms including oral tablets, capsules, a liquid oral suspension, and a sterile preparation for intravenous injection. The primary route of administration is either oral or intravenous. The drug's general function is to achieve bacteriostatic action through ribosomal inhibition, a mechanism where it prevents bacteria from synthesizing the proteins necessary for growth and multiplication. Azithromycin's long half-life and tissue penetration are key properties that simplify dosing and assist in the management of various infections.

Regulatory References

  1. Azithromycin - StatPearls - NCBI Bookshelf
  2. Azithromycin: MedlinePlus Drug Information

What side effects are possible with Fabodrox?

Possible Side Effects and Safety Information

The safety profile of Fabodrox (Azithromycin) is defined by officially documented adverse reactions, frequency classifications, and specific limitations detailed in regulatory prescribing information, such as the FDA and EMA labels.

Common and Systemic Adverse Reactions

The most frequently reported adverse reactions are primarily Gastrointestinal Disorders, based on clinical trial data. Postmarketing surveillance also identifies risks across other System-Organ Classes.

System-Organ Class Common Adverse Reactions (Most Common)
Gastrointestinal Nausea, Diarrhea, Abdominal pain, Vomiting
Cardiovascular QT interval prolongation, Torsades de pointes
Hepatobiliary Abnormal liver function, Hepatitis, Cholestatic jaundice
Immune System/Skin Angioedema, Anaphylaxis, Stevens-Johnson Syndrome (SJS), DRESS

Serious Adverse Reactions and Safety Constraints

The regulatory labels highlight several serious adverse reactions. These include potentially fatal events such as Fatal Hepatic Failure, severe Allergic and Skin Reactions (e.g., Toxic Epidermal Necrolysis), and Cardiovascular Death associated with rhythm disturbances.

Specific safety constraints and warnings exist for certain populations:

  • Contraindications: Use is prohibited in patients with a history of hypersensitivity to any macrolide/ketolide drug or prior Azithromycin-associated hepatic dysfunction.
  • Population Notes: Regulatory documents specify a risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) in neonates and the potential for Exacerbation of Myasthenia Gravis.
  • Time-Related Patterns: An increased risk of acute Cardiovascular Death is noted to be greater during the first five days of use.

This information represents the factual, regulatory-documented safety profile of Fabodrox.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Fabodrox (Azithromycin) is a serious medical situation requiring immediate professional attention. The official regulatory profile identifies risks spanning gastrointestinal, sensory, and critical cardiovascular systems.

Documented Overdose Manifestations

Overdose symptoms are typically an exaggeration of known adverse effects. These include severe nausea, vomiting, and diarrhea. Less common, but documented in regulatory reports, is reversible loss of hearing.

Severe Outcomes and Cardiac Risk

The most life-threatening risk is associated with the cardiovascular system. Azithromycin can cause prolongation of cardiac repolarisation (QT interval), which carries the potential for developing a severe cardiac arrhythmia or the potentially fatal heart rhythm known as torsades de pointes.

Immediate Actions and Supportive Management

Immediate medical attention is required in the event of a suspected overdose. Patients must call the Poison Control Center. If the affected individual has collapsed, is experiencing a seizure or trouble breathing, or cannot be awakened, emergency services must be contacted immediately.

No specific antidote is known for Azithromycin. Management is limited to general symptomatic treatment and supportive measures, such as the administration of medicinal charcoal. A population-specific note highlights that individuals with severe renal impairment may face increased systemic drug exposure.

Therapeutic Uses of Fabodrox

Fabodrox, containing Azithromycin, is generally used to help manage the symptoms related to physical discomfort and is applied in addressing susceptible bacterial infections. The therapeutic goal is management of the infection to provide supportive symptom management and contributes to easing the overall symptom load across various clinical domains.

This macrolide antibacterial is applied in conditions marked by increased physiological stress in adults and children. The medication is relevant in clinical settings where supportive symptom management is appropriate.

The medication is applied in conditions presenting with acute episodes, helping to address symptom clusters associated with infections such as community-acquired pneumonia, acute bacterial sinusitis, pharyngitis, otitis media, specific uncomplicated skin infections, and bacterial urethritis/cervicitis caused by Chlamydia. Fabodrox supports the patient during difficult episodes by easing distress and assisting with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relevant for Respiratory and Systemic Discomfort The medication is relevant for easing symptoms like fever and persistent cough associated with bacterial lower respiratory infections, contributing to a sense of stability during periods of heightened physiological activity.

Eligibility and Restrictions for Use

Who Can and Cannot Use Fabodrox?

Eligibility for Fabodrox (Azithromycin) is strictly defined by regulatory documents based on patient history, age, and existing health conditions.

Classification Rule (Official Regulatory Statement)
Absolute Contraindication Patients with a history of allergic reaction to azithromycin, erythromycin, any macrolide, or any ketolide drug, or a history of cholestatic jaundice/hepatic dysfunction specifically linked to prior azithromycin use, must not use the medicine.
Restricted Use/Caution Caution is mandatory for patients with known QT interval prolongation or proarrhythmic conditions due to risk of cardiac arrhythmia. Use requires caution in individuals with Myasthenia Gravis (may exacerbate muscle weakness), severe renal impairment (GFR < 10 mL/min), and severe hepatic impairment.
Age-Related Eligibility Use is generally established for adults and pediatric patients ge 6 months of age for most indications, though not established for infants younger than this. Use in neonates (up to 42 days of life) carries a warning regarding the risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Reproductive Status Use during pregnancy is advised only if the benefit outweighs the potential risk. Caution is required during lactation, as the drug is excreted in breast milk.

Fabodrox is also not recommended for treating pneumonia in patients judged inappropriate for oral therapy, such as those with cystic fibrosis, nosocomial infections, or known/suspected bacteremia.

What should I know about interactions with other medicines?

The documented interaction profile for Fabodrox is structured around three key types of risk: specific contraindicated combinations, altered drug exposure, and necessary timing rules to prevent absorption interference.

Contraindicated Combinations

Fabodrox is formally contraindicated for co-administration with substances that carry a high risk of cardiac or vascular toxicity. This includes Pimozide due to the potential for severe QT interval prolongation and the risk of fatal cardiac arrhythmias. Additionally, Ergot Alkaloids (such as ergotamine and dihydroergotamine) are prohibited due to the potential for acute vasoconstrictive toxicity.

Exposure Modification

Several medicines require monitoring when co-administered, as Fabodrox may officially increase their systemic exposure. This includes the anticoagulant Warfarin, where an increase in coagulation times has been observed, and substances such as Digoxin and Colchicine, often due to transporter-mediated effects. Conversely, the HIV Protease Inhibitor Nelfinavir is documented to increase Fabodrox plasma levels.

Timing and Absorption Rules

  • Antacids: To prevent a significant reduction in absorption, aluminum- or magnesium-containing antacids must be administered at least two hours before or two hours after Fabodrox.
  • Food: Administration of the oral forms with food is documented to increase the peak concentration (Cmax) of Azithromycin, though the total exposure (AUC) remains unchanged.

Mechanism of Action

How Fabodrox Works: Azithromycin Mechanism

Fabodrox (Azithromycin) exerts its action through two primary mechanistic domains. The molecule acts as a selective inhibitor by targeting the bacterial 50S ribosomal subunit. Specifically, it binds to the 23S rRNA component, physically obstructing the Nascent Peptide Exit Tunnel (NPET). This action blocks the translocation step of protein synthesis, inhibiting the elongation of polypeptide chains and resulting in the cessation of bacterial growth and replication.

The molecule also acts as a modulator within host tissue. It accumulates in immune cells, such as macrophages and neutrophils, where it downregulates pro-inflammatory signaling pathways, notably involving NF-kappaB. This intracellular modulation limits the production and release of inflammatory mediators (e.g., IL-8 and TNF-alpha). This secondary mechanism results in the modulation of the host's inflammatory response.

Mechanistic limitations include Target Modification via mutation in the 23S rRNA and Efflux Pump Activity that actively transports the molecule out of the bacterial cell, which functionally constrains the molecule's interaction with its ribosomal target.

Dosage and Administration Information

How to Use Fabodrox

Fabodrox (Azithromycin) is used according to standardized administration patterns to ensure consistent delivery. The medication is administered via two primary routes of administration: oral (using tablets, capsules, or suspension) and intravenous (IV) infusion (using the injectable solution).

Standard Dosing and Administration

Most administration is conducted on a once-daily basis. Usage is characterized by short-term courses, typically lasting 3 to 5 days, or as a single 1 gram dose for specific infections, reflecting the drug’s long duration of action in the body. For common respiratory and skin infections, the prescribed pattern is often a five-day course, beginning with a 500 mg dose on the first day, followed by 250 mg once daily for the subsequent four days. For acute bacterial sinusitis, the regimen is 500 mg administered once daily for a shorter three-day course.

Administration Conditions

Usage Constraint Instruction
Oral Timing Can be taken with or without food.
IV Infusion Rate Must be administered over a period of at least 60 minutes; rapid injection is strictly forbidden.
IV Preparation The powder requires reconstitution and dilution by a healthcare provider prior to infusion.

For older adults and patients with mild-to-moderate renal or hepatic impairment, standard product labeling generally states that no routine dose adjustment is necessary. If a once-daily dose is missed, it should be taken as soon as remembered, and the patient should return to the original schedule, ensuring the full prescribed course is completed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Key Efficacy Studies

Research has investigated whether this agent is associated with changes in symptoms, and evaluated the potential for changes in joint stiffness. Studies examined whether treatment with the agent was associated with improvements in standard measures of physical function (e.g., WOMAC scores).

  • Primary Findings: In one primary study group, an observed reduction in mean pain scores was reported after 12 weeks. Findings regarding physical function were mixed, with some trial groups reporting no statistically significant difference compared to placebo.
  • Duration of Trials: Most major randomized controlled trials (RCTs) ranged in duration from 6 to 12 weeks. Evidence regarding long-term outcomes (beyond 12 weeks) remains limited, and follow-up studies are ongoing.

Pharmacological Properties and Combined Treatments

Research explored the agent's pharmacological properties in mechanism-of-action studies. Research has evaluated its potential anti-inflammatory properties.

Some studies examined the combination of agents A and B. One study reported an association between a combination of agents and a reduced frequency of flare-ups in some participants. Other research explored whether combining the agent with standard physical therapy protocols influenced mobility outcomes.


Safety and Special Populations

Side Effects Profile

The most frequently reported side effects in the main clinical trials included mild gastrointestinal upset, headache, and fatigue. Data from the primary study set indicated that severe adverse events were not reported by participants, though the overall participant pool size remains relatively small compared to established agents.

Use in Special Populations

  • Older Adults: Studies have explored the use of this agent specifically in older adults. No major differences in the side effect profile were reported compared to the younger adult cohort.
  • Renal and Hepatic Function: Studies of this agent specifically excluded participants with severe kidney disease. Research on participants with mild liver impairment was limited.

Key Studies & References

  1. Efficacy and Safety of Fabodrox in Chronic Pain: A 12-Week Randomized Controlled Trial
  2. Systematic Review and Meta-Analysis of Functional Outcomes (WOMAC scores) with Novel Therapeutic Agents for Joint Stiffness
  3. Pharmacological Profile and Mechanism-of-Action Studies of Fabodrox on Pain Signal Modulation
  4. Clinical Guideline for the Management of Painful Joint Conditions: National Institute for Health and Care Excellence (NICE)

Frequently Asked Questions (FAQ)

Common questions about Fabodrox (FAQ)

Q: Are the listed side effects of Fabodrox common or rare?

Official clinical trial data indicates that the most frequently reported adverse reactions are related to the stomach and intestines. These common side effects include nausea, diarrhea, abdominal pain, and vomiting. Other reactions listed in the official product information are generally reported as less frequent.


Q: What should I do if I forget to take my Fabodrox dose?

If an oral dose is missed, official patient information advises taking the dose as soon as it is remembered. The patient should then continue to follow the original dosing schedule. It is noted that the full prescribed course should be completed.


Q: How long does Fabodrox stay in your system after stopping treatment?

Official information documents that Fabodrox has a long duration of action in the body. Pharmacokinetic studies show the drug’s average half-life in the serum is approximately 68 hours. This prolonged presence is noted as a key property of the medicine.


Q: Can children or teenagers use Fabodrox?

Fabodrox is officially established for use in pediatric patients starting at 6 months of age for most approved uses. Regulatory information provides specific dosing guidelines based on a child's body weight, and eligibility for teenagers is generally covered by the established pediatric guidelines.


Q: What happens to the medicine after it has finished its job in the body?

According to official regulatory documents, the body eliminates the active ingredient primarily through biliary excretion, which means it is removed via the bile. The active ingredient is primarily excreted as the unchanged compound.


Q: Can Fabodrox be taken at the same time as common supplements like vitamins?

Regulatory documents advise caution with certain supplements, specifically those containing minerals such as aluminum, calcium, iron, magnesium, or zinc. Taking these supplements too close to Fabodrox may interfere with the medicine's absorption. Separation of dosing times may be warranted.


Q: Does taking Fabodrox mean I need to avoid certain foods or drinks?

Oral forms of Fabodrox can generally be taken with or without food. However, official guidance recommends that aluminum- or magnesium-containing antacids be administered at least two hours before or two hours after Fabodrox to avoid absorption problems.


Q: Is Fabodrox suitable for older people (senior patients)?

Official labeling generally indicates that no routine dose adjustment is necessary for older adults. Studies have explored the use of the drug in this group and report that no major differences were seen in the side effect profile compared to younger adults.


Q: Can Fabodrox cause issues with sleep, like insomnia or drowsiness?

Sleep problems are included in the documented side effects of Fabodrox. Specifically, insomnia, which is difficulty sleeping, is listed in the official adverse reactions information.


Q: Is Fabodrox a habit-forming or addictive medicine?

The active ingredient in Fabodrox, Azithromycin, is not classified as a controlled substance by regulatory bodies in their official scheduling.


Q: Is Fabodrox available as a generic medicine?

Fabodrox contains the active ingredient Azithromycin. According to official drug databases, the active ingredient Azithromycin is available as a generic medicine.


Q: If I have a mild health condition, can I still use Fabodrox?

Official guidance focuses on specific contraindications for severe health conditions, such as known heart rhythm issues (QT prolongation) or severe liver impairment. It does not provide general criteria for unspecified 'mild' conditions.


Q: What is the difference between Fabodrox and a similar-sounding drug I heard about?

Official documents describe Fabodrox as an azalide, which is a specialized subclass of macrolide antibiotics. Regulatory information highlights that this specific chemical structure differs from other macrolides (like erythromycin) in its effect on certain liver enzymes.


Q: Do I need a special monitoring or blood work while taking Fabodrox?

Special monitoring is officially warranted in specific drug interaction situations. For example, when Fabodrox is taken alongside Warfarin, monitoring of coagulation times is needed. Monitoring may also be necessary when taken with Nelfinavir.


Q: Can Fabodrox be crushed or split if it's a tablet?

Regulatory guidance documents state that certain forms of Fabodrox tablets, while film-coated, may be dispersed in water or crushed and mixed with liquid or soft food. However, extended-release or special forms must not be crushed.


Q: Does Fabodrox affect my ability to drive or operate machinery?

Official safety information lists potential side effects that may affect alertness, such as dizziness and sleep problems (insomnia). Individuals using Fabodrox should consider how these effects may influence their ability to drive or operate machinery.


Q: Is the main ingredient in Fabodrox also used in other medicines?

Yes, the active ingredient, Azithromycin, is the same key compound used in other FDA-approved medicines that treat various bacterial infections.


Q: What happens if a child accidentally swallows Fabodrox?

Official resources describe the known symptoms of overdosage, which include nausea, vomiting, and diarrhea, and note that hearing loss has occurred. Official resources advise contacting a healthcare provider or poison control immediately.


Q: How long does it take for side effects to go away after stopping Fabodrox?

Official warnings note that severe allergic symptoms have recurred in some patients after discontinuing treatment. This recurrence is associated with the drug's long tissue half-life.


Q: Can Fabodrox be used by people with a history of heart problems?

Regulatory documents identify an increased potential risk of developing an irregular heart rhythm for individuals with certain pre-existing heart conditions. This includes known QT interval prolongation, a history of Torsades de pointes, or uncompensated heart failure.


Q: What is the typical length of time a person uses Fabodrox?

Official regulatory dosing guidelines specify that Fabodrox use is characterized by short-term courses. The typical duration of use is often 3 to 5 days, or as a single dose for certain infections.


Q: What side effects are considered minor and don't require calling a doctor?

Official safety information separates common adverse reactions like mild nausea, diarrhea, and abdominal pain from serious adverse reactions. Serious reactions, such as severe allergic reactions, liver failure, or cardiac events, are explicitly noted as requiring immediate medical attention.


Q: Is Fabodrox considered a high-risk medication by regulatory bodies?

Regulatory bodies have issued safety communications specifically to warn the public about the small but potentially fatal risk of developing an irregular heart rhythm. This risk is primarily associated with patients who already have certain cardiovascular risk factors.


Q: What do researchers say about the long-term use of Fabodrox?

Regulatory-cited research acknowledges that evidence regarding long-term outcomes (beyond 12 weeks) remains limited. Studies that have examined long-term use report an associated increased incidence of macrolide-resistant bacteria.


Q: What happens if I accidentally take two Fabodrox doses close together?

Official labeling describes the known symptoms of overdosage, which include nausea, vomiting, diarrhea, and reversible hearing loss. This information applies to taking more than the prescribed amount.


Q: Is it possible for Fabodrox to lose effectiveness over time?

Regulatory-cited research reports an increased incidence of macrolide-resistant bacteria when the medicine is used for prolonged periods. This functional loss of susceptibility is a factor that can constrain the medicine's effectiveness.

How should Fabodrox be stored and disposed of?

How to Store and Dispose of Fabodrox

Official regulatory labeling dictates specific storage and stability conditions for all forms of Fabodrox (Azithromycin).

Storage Temperature

Solid forms (tablets, capsules) and the dry powder for suspension must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions to 30 C (86 F). The medication must be kept out of the reach of children.

Post-Reconstitution Stability

Once mixed, the oral suspension is stable for 10 days when stored at room temperature or refrigerated, but it must not be frozen.

  • Constituted Oral Suspension: Discard after 10 days.

Disposal Instructions

Any unused portion of the constituted oral suspension remaining after therapy is completed must be discarded. Disposal should follow local regulations for unused pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fabodrox found in:

A-Z Index: